Forecast

Buy	1
Hold	0
Sell	0

News Go to news feed

BioHarvest Sciences presents scaling plans and new production facility for plant-cell platform

At an investor conference BioHarvest Sciences presented its "Botanical Synthesis" platform, announced an expansion of production and a new facility with 20–25 tonnes capacity, and highlighted roughly $100 million in investments and 15 patents. Revenue in 2025 was about $35 million, VINIA cumulative revenue exceeded $100 million; for 2026 a D2C revenue of $33–35 million and consolidated revenue of $37–40 million is expected. The company cited a supply agreement for a fragrance molecule totaling 20 tonnes (valued at $20–30 million for 2027–28) and says it holds 20% of that molecule as well as 25% of a saffron molecule. BioHarvest emphasizes shifting the business from development revenue toward manufacturing and royalties and is using AI for process optimization and quality control. » More on de.investing.com
BioHarvest Sciences Q1 revenue rises 8% as CDMO and D2C operations advance

BioHarvest Sciences reported Q1 revenue of $8.5m, up 8% year‑over‑year, and maintained full‑year guidance of $42m–$48m. CDMO revenue grew 135% driven by progress in fragrance and saffron Botanical Synthesis programs, including Stage 2 agreements valued at over $2m. Net loss widened to $2.6m and adjusted EBITDA loss was $1.2m; cash totaled $20.2m at quarter end. The VINIA D2C business accounted for 95% of sales with 90,000 active users and new product momentum, while the company plans a new manufacturing site operational in H2 2027 and named Nedira Salzman‑Frenkel VP of CDMO business development. » More on finance.yahoo.com
BioHarvest Sciences: VINIA becomes leading resveratrol brand in the US

BioHarvest Sciences reports that its brand VINIA became the largest resveratrol dietary supplement brand in the US in 2025, based on NielsenIQ forecasts and Amazon sales data. VINIA generated over USD 30 million in US sales in 2025 and about USD 85 million in cumulative global sales; the last twelve months through Q3/2025 delivered USD 32.72 million (+46% year‑on‑year). The company shows an EPS of -0.68 USD but a gross margin of 59%; roughly 80% of US sales come from direct‑to‑consumer business via VINIA.com. BHST shares trade near a 52‑week low at USD 4.36, while analyst targets of USD 10–15 indicate significant upside potential. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2023, BIOHARVEST SCIENCES INC has already paid 0,47€ in dividends. The last payout was in September 2023.

Financials

In the last year, BIOHARVEST SCIENCES INC had revenue of 24.21m€ and net profit of −12.41m€

(EUR)	2024	YoY
Revenue	+24.21m	111,16%
Gross profit	+13.40m	162,94%
Net profit	−12.41m	9,19%
EBITDA	−6.65m	24,74%

Fundamentals

Metric	Value
Market capitalization	+85.35m€
Number of shares	17.33m
52-week high/low	+5,70€ - +0,12€
Dividends	No
Beta	1,51
P/E ratio	−7,17
PEG ratio	+0,37
P/B ratio	+69,83
P/S ratio	+3,95

Company profile

BioHarvest Sciences Inc. bietet zusammen mit seinen Tochtergesellschaften in Israel und auf internationaler Ebene Superfrüchte und Cannabisprodukte an. Seine Technologie zur Züchtung von Pflanzenzellen produziert die aktiven Sekundärmetaboliten, ohne dass die Pflanze selbst gezüchtet werden muss. Das Unternehmen entwirft, entwickelt, produziert und vermarktet Vinia, ein nutrazeutisches Produkt aus rotem Traubenpulver, sowie medizinisches Cannabis. BioHarvest Sciences Inc. hat seinen Sitz in Vancouver, Kanada.